# Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")

> **NCT03400254** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Abramson Cancer Center at Penn Medicine**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Hydroxychloroquine (HCQ)
- **DRUG:** Gedatolisib

## Key facts

- **NCT ID:** NCT03400254
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-02-26
- **Primary completion:** 2019-08-30
- **Final completion:** 2019-11-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** due to business decision regarding the study drug.
- **Last updated:** 2020-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03400254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03400254, "Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03400254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*